We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 401.08 | 400.50 | 404.57 | 35 | 11:10:47 |
From May 2019 to May 2024
By Colin Kellaher
Vertex Pharmaceuticals Inc. on Friday said the European Commission approved Kaftrio in combination with ivacaftor to treat people ages 12 and over with cystic fibrosis.
The Boston drug maker said the approval covers the combination in patients with one F508del mutation and one minimal function mutation, or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene.
The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended approval of the combination.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 21, 2020 09:31 ET (13:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
